TITLE

Non-alcoholic and alcoholic Fatty Liver Disease - two Diseases of Affluence associated with the Metabolic Syndrome and Type 2 Diabetes: the FIN-D2D Survey

AUTHOR(S)

Kotronen, Anna; Yki-Järvinen, Hannele; Männistö, Satu; Saarikoski, Liisa; Korpi-Hyövälti, Eeva; Oksa, Heikki; Saltevo, Juha; Saaristo, Timo; Sundvall, Jouko; Tuomilehto, Jaakko; Peltonen, Markku

PUB. DATE

January 2010

SOURCE

BMC Public Health;2010, Vol. 10, p237

SOURCE TYPE

Academic Journal

DOC. TYPE

Article

ABSTRACT

Background: Non-alcoholic fatty liver disease (NAFLD) is known to be associated with the metabolic syndrome (MetS) and abnormal glucose tolerance. Whether alcoholic fatty liver disease (AFLD) is associated with similar metabolic abnormalities has not been examined in a population-based study. We aimed at assessing the prevalences of NAFLD and AFLD, and to examine to what extent these conditions are associated with MetS and abnormal glucose tolerance. Methods: The cohort included 2766 Finnish subjects (45-74 years) from the population-based FIN-D2D survey. Features of insulin resistance, components of the MetS, glucose tolerance status by oral glucose tolerance test, serum liver enzyme concentrations, and daily alcohol consumption were assessed. Results: Subjects with NAFLD and AFLD were equally obese and had similar fasting and insulin concentrations. The prevalences of NAFLD and AFLD were 21% (95% CI: 19%-22%) and 7% (95% CI: 6%-8%). The MetS was slightly more prevalent in AFLD (73%) than in NAFLD (70%, p = 0.028), and type 2 diabetes was similarly prevalent in NAFLD and AFLD (24-25%). The MetS and type 2 diabetes were more prevalent in subjects with NAFLD or AFLD compared to subjects with normal LFTs (53% and 14%, p < 0.0001 for both). Discussion and conclusion: In Finnish middle-aged population, the prevalence of NAFLD is 3-fold higher than that of AFLD. The prevalences of MetS and type 2 diabetes are, however, significantly increased in both NAFLD and AFLD compared to subjects with normal LFTs. Subjects with AFLD are thus similarly metabolically unhealthy as subjects with NAFLD.

ACCESSION #

51137993

 

Related Articles

• Hepatic steatosis, carotid atherosclerosis and metab olic syndrome: the STEATO Study. Carallo, Claudio; Mancuso, Gerardo; Mauro, Gaetano; Laghi, Ferdinando; Madafferi, Bruno; Irace, Concetta; Gnasso, Agostino; Scavelli, Faustina; Dell’Aquila, Ferruccio; Bartone, Mosè; Gullo, Francesco; Ferraro, Maria; Spagnuolo, Vitaliano; Belmonte, Maria; Ferrara, Antonio; Rotondaro, Antonio; Brandolino, Nicola; Parasporo, Francesca; Scopelliti, Francesco // Journal of Gastroenterology;Nov2009, Vol. 44 Issue 11, p1156 

  Hepatic steatosis is frequently observed in subjects with metabolic syndrome (MS). In type 2 diabetics, it is independently associated with cardiovascular diseases. In order to confirm and extend this finding, a large group of patients with risk factors for atherosclerosis was studied. Carotid...

• The Metabolic Syndrome.  // Current Medical Literature: Diabetes;2006, Vol. 23 Issue 1, p22 

  The article presents abstracts of research on metabolic syndrome. These include "Insulin Resistance, the Metabolic Syndrome, and Incident Cardiovascular Events in the Framingham Offspring Study," by M. K. Rutter, J. B. Meigs and L. M. Sullivan, "Liver Markers and Development of the Metabolic...

• New onset diabetes: can it be delayed? Vasisht, K P; Bakris, G // Journal of Human Hypertension;Aug2008, Vol. 22 Issue 8, p517 

  The author reports on the international rise in new onset, or type 2, diabetes. Details about some of the factors that cause impaired glucose tolerance to become type 2 diabetes, such as increased body mass index (BMI) and metabolic syndrome, are included. The article also discusses the need to...

• Cost-utility analyses of intensive blood glucose and tight blood pressure control in type 2 diabetes (UKPDS 72). Clarke, P.M.; Gray, A.M.; Briggs, A.; Stevens, R.J.; Matthews, D.R.; Holman, R.R. // Diabetologia;May2005, Vol. 48 Issue 5, p868 

  Aims/hypothesis: This study estimated the economic efficiency (1) of intensive blood glucose control and tight blood pressure control in patients with type 2 diabetes who also had hypertension, and (2) of metformin therapy in type 2 diabetic patients who were overweight. Methods: We conducted...

• Questioning the assumptions about type 2 diabetes. Lipscombe, Lorraine L.; Detsky, Allan S. // CMAJ: Canadian Medical Association Journal;8/5/2014, Vol. 186 Issue 11, p880 

  The article discusses the assumptions that are the basis of clinical practice guidelines for type 2 diabetes which resulted to an increase in the number of patients receiving multiple lifelong therapies. Topics discussed include one assumption that type 2 diabetes is a progressive and...

• Two-Step Approach for the Prediction of Future Type 2 Diabetes Risk. ABDUL-GHANI, MUHAMMAD A.; ABDUL-GHANI, TAMAM; STERN, MICHAEL P.; KARAVIC, JASMINA; TUOMI, TIINAMAIJA; BO, INSOMA; DEFRONZO, RALPH A.; GROOP, LEIF // Diabetes Care;Sep2011, Vol. 34 Issue 9, p2108 

  OBJECTIVE--To develop a model for the prediction of type 2 diabetes mellitus (T2DM) risk on the basis of a multivariate logistic model and 1-h plasma glucose concentration (1-h PG). RESEARCH DESIGN AND METHODS--The model was developed in a cohort of 1,562 nondiabetic subjects from the San...

• Differential Effects of Comorbidity on Antihypertensive and Glucose-Regulating Treatment in Diabetes Mellitus - A Cohort Study. Voorham, Jaco; Haaijer-Ruskamp, Flora M.; Wolffenbuttel, Bruce H. R.; Dick de Zeeuw; Stolk, Ronald P.; Petra Denig // PLoS ONE;Jun2012, Vol. 7 Issue 6, p1 

  Background: Comorbidity is often mentioned as interfering with "optimal" treatment decisions in diabetes care. It is suggested that diabetes-related comorbidity will increase adequate treatment, whereas diabetes-unrelated comorbidity may decrease this process of care. We hypothesized that these...

• Focus on Fiber, not Fat. O., J. // School Health Alert;Jan2012, Vol. 27 Issue 5, p1 

  The article offers information on metabolic syndrome (MetS), which is a physical factor associated with cardiovascular disease and type 2 diabetes. It states that MetS is also defined as blood pressure, high waist circumference, serum triglycerides and serum glucose. It mentions that its...

• Bypass of Metabolic Diseases With Surgery. Dohm, G. Lynis; Pories, Walter J. // Obesity (19307381);Jul2011, Vol. 19 Issue 7, p1323 

  In this article, the authors discuss the significant effects of gastric bypass surgery, including remission of type 2 diabetes mellitus (T2DM) and lower mortality rates. A study on the mechanisms of the effects showed that a remission of the metabolic syndrome is due to a correction of the...

Read the Article